Should I Buy IPX? IPX 2026 Analysis

Should You Buy Iperionx Ltd (IPX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

50.120

1 Day change

-5.10%

52 Week Range

61.450

Analysis Updated At

2026/01/29

IPX is not a good buy right now for an impatient investor. Despite longer-term bullish moving averages, the stock just sold off hard (-7.07% regular session) and has no Intellectia buy signals today, while the most prominent analyst commentary is a strongly bearish forensic-style note alleging overvaluation and potential reporting concerns. With limited confirmed near-term catalysts (a small initial order) and no supportive sentiment signals from options/insiders/congress data, the risk/reward is unfavorable for an immediate entry.

Technical Analysis

Trend/structure: Bullish longer-term structure with SMA_5 > SMA_20 > SMA_200, but the latest session showed a sharp downside move, indicating near-term weakness/instability. Momentum: MACD histogram is positive (0.531) but contracting, implying bullish momentum is fading rather than accelerating. RSI_6 ~49.96 is neutral, offering no oversold bounce signal. Key levels: Pivot 53.537 is the key near-term line—price (54.92) is only slightly above it, so losing this area can open a move toward S1 47.576 (then S2 43.893). Upside resistance sits at R1 59.498 then R2 63.181. Pattern-based forward bias: Similar-pattern stats imply ~-0.98% over the next week and +3.83% over the next month—i.e., choppy/uncertain near term. Intellectia Proprietary Trading Signals: **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): no signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Positive Catalysts

and reclaims resistance.

Neutral/Negative Catalysts

- A major bearish research note (Spruce Point) flags potential overvaluation and questions around commercial execution; it also raises concerns about financial reporting accuracy and suggests severe downside scenarios (70%–95%).
- Recent price action is risk-off: -7.07% regular-session drop signals distribution/weak demand at current levels.
- No Intellectia proprietary buy signals (neither AI Stock Picker nor SwingMax), reducing conviction for an immediate entry.
- Sentiment/trading activity signals are not supportive: hedge funds and insiders are neutral; no congress trades to indicate influential accumulation.
- The Rheinmetall order is small in dollar terms ($0.3M), so near-term fundamental impact may be limited unless it scales.

Financial Performance

Financial snapshot was not available (data error: "list index out of range"), so latest-quarter growth trends and the latest quarter season cannot be verified from the provided data. Based on available inputs, there is insufficient evidence of near-term accelerating fundamentals to justify buying immediately after a sharp selloff.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst trend: The only provided analyst coverage is a highly negative note dated 2025-11-12 from Spruce Point Capital. It argues expectations are too high, questions the attractiveness of end markets and the likelihood that the HAMR process is transformative, and raises concerns about reporting accuracy. It frames the stock as potentially significantly overvalued with extreme downside risk (70%–95%). Wall Street pro/con view from the provided data: Pros are limited to the strategic ambition (vertical integration, titanium powder/products) and potential customer validation; cons dominate due to valuation skepticism, execution risk, and credibility/reporting concerns.

Analyst Rating

Wall Street analysts forecast IPX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IPX is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 52.810

Low

Averages

High

Current: 52.810

Low

Averages

High

Spruce Point Capital

downgrade

AI Analysis

2025-11-12

Reason

Spruce Point Capital

Price Target

AI Analysis

2025-11-12

downgrade

Reason

Spruce Point Capital, in a research note, said that after conducting a forensic review of IperionX and its ambitions of becoming a vertically integrated producer of titanium powders and products, the firm believes that investor expectations are too high, and it faces significant challenges in commercial efforts that may not be fully reflected in its valuation. Spruce Point also expressed concerns with the accuracy of its financial reporting and says it does not believe the end markets to be attractive or that its highly promoted HAMR process is likely to "revolutionize" the industry. Based on the firm's analysis, Spruce Point advises investors to exercise caution because the shares may be significantly overvalued, with potential downside risk of 70% - 95% under certain scenarios. Reference Link

Roth Capital

Buy

maintain

$64 -> $74

2025-10-01

Reason

Roth Capital

Price Target

$64 -> $74

2025-10-01

maintain

Buy

Reason

Roth Capital raised the firm's price target on IperionX to $74 from $64 and keeps a Buy rating on the shares. The firm cites the company's FY25 results and the receipt of additional government funding as part of its existing $47.1M award, the analyst tells investors in a research note. Roth adds that its higher price target reflects lower future dilution assumptions and a higher multiple on 2029 EBITDA.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IPX

Unlock Now

IPX Should I Buy

IPX Should I Buy

Should You Buy Iperionx Ltd (IPX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch